BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 8517457)

  • 1. Sources of regulatory information for pharmacists.
    Goldwire MA; Rumore MM
    Am J Hosp Pharm; 1993 Jun; 50(6):1175-81. PubMed ID: 8517457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
    Grant KL
    Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational drug tracking: phases I-III and NDA submissions--Part II.
    Grant KL
    Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory aspects of investigational new drugs.
    Arbit HM
    Am J Hosp Pharm; 1978 Jan; 35(1):81-5. PubMed ID: 341700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
    Kock M; Thomsen MK
    Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician dispensing: issues of law, legislation and social policy.
    Abood RR
    Am J Law Med; 1989; 14(4):307-52. PubMed ID: 2729291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A physician's guide to information available from the FDA about new drug approvals. The ACG Committee on FDA-related matters. American College of Gastroenterology.
    Hassall TH; Fredd SB
    Am J Gastroenterol; 1989 Oct; 84(10):1222-6. PubMed ID: 2801669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues.
    Mackler BF; Barach M
    J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation.
    Zalesky CD
    J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of enforcement controlled substance laws in health policy for prescribing opiate medications: a painful assessment of morbidity and mortality.
    Miller NS
    Am J Ther; 2006; 13(6):527-33. PubMed ID: 17122534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computer-assisted investigational drug information and testing mechanism for nurses.
    Wermeling DP; Nowak-Rapp M; Sitzlar S
    Hosp Pharm; 1994 Aug; 29(8):745-6, 748-50. PubMed ID: 10135743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.